Our company is centered around the Chronic Condition Mapping Package Initiative (CCMPI), a project which aims to track the completeness, consistency, and accuracy of chronic condition diagnoses within EMRs. Specifically, we are looking for partners to provide both funding and professional networks from which we can build up the company and connect it with payers, EMRs, and hospitals/clinical administration systems. The CCMP is a groundbreaking initiative with clear effects on patients and their health. Specifically, improved chronic condition diagnosis record keeping would reduce inaccurate diagnoses, reduce unnecessary repeat diagnostic testing, improve personalized treatment plans, improve the research basis for diagnosis/prognosis/treatment plans, and countless other benefits directly to patients.
The CCMP would provide countless improvements to healthcare systems, including reduction of skilled healthcare human capital usage from missing/inaccurate chronic condition diagnosis information, reduced costs associated with mismanagement of chronic conditions, improved population health outcomes, and many other improvements. Information flow would be the direct benefit of the CCMP by providing complete, consistent, and accurate chronic condition diagnosis data. In terms of Telehealth, CCMP would be able to incorporate notes and data from telehealth encounters and incorporate it within the framework of CCMP analysis. Specifically, Telehealth could be viewed within the context of general information of an EMR and also separately as a point of comparison to see whether chronic condition diagnoses are being effectively managed within the Telehealth setting.
Prostate cancer is targeted using a patent GPS system that turns every ultrasound into a 3D US with navigation capabilities and superimposing (fusing) MRI and or CT images to provide a multi-layer diagnostic tool and guidance for targeted needle placement. This technology allows for a 31% increase in detection rate and impacts the treatment plan for most patients by avoiding severe side effects like impotence and incontinence.
We are increasing our market presence and looking for investments to grow our sales force. we are riding the revolution of prostate cancer, the most common cancer among men, impacting as many as 1 of every 6-7 men. Urologists and interventional radiologists are seeking better diagnostic tools, better follow-up capabilities and higher detection rates to provide a smarter treatment plan. For the first time, biopsies are documented, cancer location are 3D visualized and follow-ups are recorded on a 3D map of the prostate. the whole patient treatment history is visualized. We allow the patient to share information with physicians in a visualized manner, monitor their disease closely and understand the treatment plan and risks.